Wikipedia:Articles for deletion/Concept Medical


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was keep‎__EXPECTED_UNCONNECTED_PAGE__. Extraordinary Writ (talk) 00:01, 17 December 2023 (UTC)

Concept Medical

 * – ( View AfD View log | edits since nomination)

Fails to meet Wikipedia's notability guidelines for corporations, as explained in WP:NCORP and WP:ORGCRIT. WP:PROMO: Sponsored content published at supplements (WP:NEWSORGINDIA). Charlie (talk) 17:52, 2 December 2023 (UTC)
 * Note: This discussion has been included in the deletion sorting lists for the following topics: Companies and India. Charlie (talk) 17:52, 2 December 2023 (UTC)
 * Note: This discussion has been included in the deletion sorting lists for the following topics: Medicine, Technology,  and Florida.  WC  Quidditch   ☎   ✎  18:56, 2 December 2023 (UTC)
 * Delete Keep Their biggest strength is probably the drug-coated balloon treatments for arteries, but I can only find routine coverage. $60m funding sure is a lot though . Darcyisverycute (talk) 11:31, 3 December 2023 (UTC)
 * Although most of the sources are routine coverage, I can now see independent sources with significant coverage that VikingsKhan has found and helpfully integrated into the article. Receiving an award from the then-president is also highly notable. Darcyisvery cute (talk) 01:07, 14 December 2023 (UTC)

Please add new comments below this notice. Thanks, Daniel (talk) 21:33, 9 December 2023 (UTC)
 * Keep "A company, corporation, organization, group, product, or service is presumed notable if it has been the subject of significant coverage in multiple reliable secondary sources that are independent of the subject." (Primary Criteria section at WP:CORP) Just look at the sources used. Seems to exceed this criteria. MaxineJP (talk) 13:53, 7 December 2023 (UTC)
 * Keep: per WP:NORG. The subject passes the Notability guidelines and it receives IDE approval from the Food and Drug Administration, see . I really agree with WP:NEWSORGINDIA but this can't be used in every article. I went through the Nominators account and got that the editor is just Nominating pages for AfD. Earlier nominated other notable articles like Gulf Giants, Abu Dhabi Knight Riders and other articles nominated by the editor are minimally participated. — Syed A. Hussain Quadri (talk) 16:41, 8 December 2023 (UTC)
 * @QuadriOnMobile The nomination's basis is evident and straight-forward, and this company fails WP:NORG. Even when considering the FDA's IDE approval as suggested by you, which essentially permits the device's use in clinical investigations to assess its safety and effectiveness. And, according to guidelines like WP:MEDPRI, findings are frequently highlighted in the media immediately after initial research is released, often before the scientific community has had the chance to thoroughly analyze and provide feedback on the results. To understand how important these studies are, it's better to use reliable information from other trusted sources instead of using news stories or press releases based on those on-going research and its outcomes.
 * If you are willing, I kindly request your assistance in improving this page to meet the Heymann standard or offering supportive source analysis, as it would greatly benefit Wikipedia. However, it's important to focus on the present nomination without referencing past nominations that aren't relevant here. If there are concerns regarding my recent AfD nominations or any doubts with respect to it, I encourage you to communicate them in an appropriate forum, and I will be more than willing to address them there. Charlie (talk) 03:53, 9 December 2023 (UTC)
 *  Relisted to generate a more thorough discussion and clearer consensus.


 * Comment: I started this page with some basic info and was hoping others would pitch in to turn it into a detailed article. There's a wealth of information about the company online, and here's why we should keep this page:


 * 1) The company has a lot of coverage by reliable sources. Provided two links with significant coverage about the company Outlook Business and Tampa News.
 * 2) The company developed the world's first Sirolimus-coated balloon known as Magic Touch, which received CE approval. It has been the subject of ongoing clinical studies in the United Kingdom, Italy and Brazil. It is also the most clinically studied Sirolimus Drug Coated Balloon (DCB) for PAD treatment.https://www.researchgate.net/publication/323319118_Magic_Touch_preliminary_clinical_evidence_with_a_novel_Sirolimus_drug_coated_balloon https://www.researchgate.net/publication/357084913_MagicTouch_PTA_Sirolimus_Coated_Balloon_for_Femoropopliteal_and_Below_the_Knee_Disease_Results_From_XTOSI_Pilot_Study_Up_To_12_Months https://www.researchgate.net/publication/346430511_Early_6_months_results_of_a_pilot_prospective_study_to_investigate_the_efficacy_and_safety_of_sirolimus_coated_balloon_angioplasty_for_dysfunctional_arterio-venous_fistulas_MAgicTouch_Intervention_Lea https://www.researchgate.net/figure/Fig-1-Different-generations-of-drug-coated-balloons-DCBs-The-1-st-and-2-nd_fig1_322125982 https://www.researchgate.net/publication/341769593_Mid-term_clinical_outcomes_from_use_of_Sirolimus_coated_balloon_in_coronary_intervention_data_from_real_world_population
 * 3) The Indian government gave it the National Technology Award, and it was the top medical device exporter in India.
 * 4) It's one of the top three manufacturers in Asia.
 * 5) The International Book of Records called it the ‘Fastest Growing Medical Device Company in the Indian Stent Market.

I will be incorporating all this valuable information and citing the sources to enhance the page.VikingsKhan (talk) 15:58, 10 December 2023 (UTC)


 * @VikingsKhan These research papers focus on a product, not the company. But, please feel welcome to update the page as you prefer and improve it to meet WP:HEY. Charlie (talk) 17:45, 11 December 2023 (UTC)

Strongly Keep: I have significantly enhanced the article by incorporating additional information and sources to highlight the company's notability


 * 1) It is the first and only company to develop the world's first sirolimus-drug coated balloon called MagicTouch. This product has earned the company widespread recognition and accolades. The media, both nationally and internationally, has extensively discussed this.
 * 2) The product was granted the Breakthrough Device designation and IDE approvals from the USFDA for treating superficial femoral arteries (SFA). Extensively studied globally in various clinical trials, such as the Eastbourne registry, Nanolute, and ongoing trials like Transform 1, Transform 2, Ginger, Titan, and Hybrid Bifurcation DEB.
 * 3) Dr. Martin Leon, founder of the Cardiovascular Research Foundation and leads the IDE trials, said that the "FDA approval for the MAGICAL-SV clinical trial using the MagicTouch sirolimus-covered balloon with nanolute technology is a significant milestone in their ongoing effort to find the best therapy for managing patients with small vessel coronary obstructive disease."
 * 4) The Indian Government has awarded the company the National Technology Award for its innovations in the cardiovascular space and drug delivery devices. It is Asia's largest producer of DCB and DES, and one of the top three medical device companies in India by market share.  In 2021-22, the company was the largest medical device exporter from India and given an award by the President Ram Nath Kovind. The International Book of Records named it the Fastest Growing Medical Device Company in the Indian Stent Market.
 * 5) the company received a substantial $60 million funding from Kiran C Patel, a renowned cardiologist and businessman, specifically for conducting clinical studies on cardiac devices.
 * 6) MagicTouch is currently the only globally approved sirolimus-coated balloon with CE certification and with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. More than 100 thousand patients have been treated with MagicTouch SCB in these markets.
 * 7) It is the most extensively studied sirolimus-coated balloon for peripheral artery disease (PAD) treatment and is the focus of ongoing clinical studies in the United Kingdom, Italy, and Brazil.
 * 1) the company received a substantial $60 million funding from Kiran C Patel, a renowned cardiologist and businessman, specifically for conducting clinical studies on cardiac devices.
 * 2) MagicTouch is currently the only globally approved sirolimus-coated balloon with CE certification and with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. More than 100 thousand patients have been treated with MagicTouch SCB in these markets.
 * 3) It is the most extensively studied sirolimus-coated balloon for peripheral artery disease (PAD) treatment and is the focus of ongoing clinical studies in the United Kingdom, Italy, and Brazil.
 * 1) It is the most extensively studied sirolimus-coated balloon for peripheral artery disease (PAD) treatment and is the focus of ongoing clinical studies in the United Kingdom, Italy, and Brazil.
 * 1) It is the most extensively studied sirolimus-coated balloon for peripheral artery disease (PAD) treatment and is the focus of ongoing clinical studies in the United Kingdom, Italy, and Brazil.

I have also refined the sourcing and included additional sources that provide substantial coverage. All these collectively highlight the company's notability and meets the NCORP.VikingsKhan (talk) 17:25, 13 December 2023 (UTC)


 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.